INfusion VErsus STimulation in Parkinson's Disease
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Both Continuous intrajejunal Levodopa Infusion (CLI) and Deep Brain Stimulation (DBS) are
accepted therapies for the treatment of advanced Parkinson's disease (PD). To date, no
comparative studies have been executed. The INVEST study is an open label randomised
controlled trial with cost-effectiveness as primary outcome. Secondary outcomes will be
quality of life, neurological impairments, among others.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa